Champions Oncology, Inc. (NASDAQ:CSBR), which is in the life sciences business, and is based in United States, saw significant share price movement during recent months on the NASDAQCM, rising to highs of US$8.99 and falling to the lows of US$5.40. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Champions Oncology's current trading price of US$5.88 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Champions Oncology’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
What's the opportunity in Champions Oncology?
Great news for investors – Champions Oncology is still trading at a fairly cheap price. My valuation model shows that the intrinsic value for the stock is $10.85, but it is currently trading at US$5.88 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, Champions Oncology’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.
What does the future of Champions Oncology look like?
Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. In Champions Oncology’s case, its revenues over the next few years are expected to grow by 85%, indicating a highly optimistic future ahead. If expense does not increase by the same rate, or higher, this top line growth should lead to stronger cash flows, feeding into a higher share value.
What this means for you:
Are you a shareholder? Since CSBR is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.
Are you a potential investor? If you’ve been keeping an eye on CSBR for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy CSBR. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.
Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Champions Oncology. You can find everything you need to know about Champions Oncology in the latest infographic research report. If you are no longer interested in Champions Oncology, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.